ITCI - Intra-Cellular Therapies, Inc.

Discussion in 'Stock Message Boards NYSE, NASDAQ, AMEX' started by stock1234, Sep 28, 2016.

  1. stock1234

    stock1234 2017 Stockaholics Contest Winner

    Joined:
    Apr 3, 2016
    Messages:
    5,584
    Likes Received:
    4,619
    [​IMG]
    Intra-Cellular Therapies, Inc., a biopharmaceutical company, discovers and develops small molecule drugs for the treatment of neuropsychiatric and neurologic disorders within the central nervous system (CNS). Its lead drug candidate is ITI-007, which is in phase III clinical development for the treatment of schizophrenia and bipolar depression, as well as to treat behavioral disturbances associated with dementia, sleep disturbances associated with neurologic and psychiatric disorders, sleep and behavioral disturbances associated with autism spectrum disorder, and depression and other mood disorders. The company also develops ITI-002 phosphodiesterase type 1 (PDE1) program that is in phase I development for the treatment of central nervous system, cardiovascular, and other disorders; and PDE2 and PDE9 targets for treating neurodegeneration and bioenergetic failure in various CNS diseases. It has a license and collaboration agreement with Takeda Pharmaceutical Company Limited to research, develop, and commercialize its proprietary compound ITI-214 and other selected compounds that selectively inhibit PDE1 for use in the prevention and treatment of human diseases. The company is headquartered in New York, New York.
     
  2. stock1234

    stock1234 2017 Stockaholics Contest Winner

    Joined:
    Apr 3, 2016
    Messages:
    5,584
    Likes Received:
    4,619
    Intra-Cellular Therapies (ITCI) Stock Plunges on Schizophrenia Drug Failure, Downgrade

    NEW YORK (TheStreet) -- Shares of Intra-Cellular Therapies (ITCI) were tumbling 65.41% to $14.60 on heavy trading volume pre-market Thursday as the biopharmaceutical company's phase III trial of its schizophrenia drug was unsuccessful.

    The drug failed to reduce patients' schizophrenia symptoms when compared to a placebo. A third set of patients was given risperidone, an approved schizophrenia drug, and saw their symptoms improve.

    TheStreet's
    Adam Feuerstein said blaming the study's failure on a high placebo response rate "falls flat" since risperidone had "no trouble" beating the same placebo.

    SunTrust subsequently downgraded the New York-based company's stock to "neutral" from "buy" and cut its price target to $15 from $60 based on the trial results, according to TheFly.

    Additionally, Leerink slashed its price target to $29 from $95, but said the recent selloff was "overdone." The firm reiterated its "outperform" rating.

    Leerink added that the schizophrenia drug should not "be assumed dead." Intra-Cellular can still file for the drug's approval with the FDA and the company has other drug developments underway.

    Piper Jaffray
    analysts called the selloff a "buying opportunity," TheFly reports.

    The firm reduced the company's price target to $22 from $57 and maintained its "overweight" rating.

    Piper Jaffray said it still believes the drug is a viable, differentiated drug candidate for treating psychosis and other symptoms.

    About 1 million of the company's shares have changed hands so far today vs. its average volume of 498,705 shares per day.

    Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author. TheStreet Ratings has this to say about the recommendation:

    TheStreet Ratings team rates Intra-Cellular Therapies as a Sell with a ratings score of D+. This is driven by a number of negative factors, which it believes should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks it covers. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and generally disappointing historical performance in the stock itself.

    https://www.thestreet.com/story/138...-on-schizophrenia-drug-failure-downgrade.html





     
  3. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    9,524
    Likes Received:
    3,526
    That is the worst thing about these drug stocks, one bad failure and all gains are wiped in a flash!
     
  4. fireopal

    fireopal Well-Known Member

    Joined:
    Apr 18, 2016
    Messages:
    2,278
    Likes Received:
    517
    Might wanna keep this one on radar - @Neil Allen posted some info in the daily thread that me checking news

    INtra-Cellular Therapies Announces Commencement of Enrollment of a Clinical Trial Evaluating ITI-214 in Patients with Parkinson’s Disease -https://finance.yahoo.com/news/intra-cellular-therapies-announces-commencement-120000654.html

    Intra-Cellular Therapies Announces Closing of $150 Million Public Offering of Common Stock - https://finance.yahoo.com/news/intra-cellular-therapies-announces-closing-200100720.html
     

Share This Page